Synonym: 4SC-301; N-(5-Benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-4-thiazolecarboxamide; N-(6-Benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-4-thiazolecarboxamide; SC 75741; V1810
CAS Number: 913822-46-5
Empirical Formula (Hill Notation): C29H23N7O2S2
Molecular Weight: 565.67
Linear Formula: C29H23N7O2S2
Product Type: Chemical
| assay |
≥97% (HPLC) |
| color |
white to beige |
| form |
powder |
| SMILES string |
O=C(C1=CSC(C2CCN(C3=C4C(C=CS4)=NC=N3)CC2)=N1)NC5=NC6=CC(C(C7=CC=CC=C7)=O)=CC=C6N5 |
| solubility |
DMSO: 2 mg/mL, clear |
| storage temp. |
2-8°C |
| Biochem/physiol Actions: |
SC75741 (4SC-301; V1810) is a potent NF-kappaB (NF-κB) inhibitor (IC50 = 200 nM against 10 ng/mL TNF-α-induced NF-κB reporter gene expression in A549 cells) that impairs p65 subunit (RelA) DNA-binding activity without affecting p65 phosphorylation or nuclear translocation, nor proteasome-mediated IκBα degradation. SC75741 induces apoptosis in multiple myeloma cultures (IC50 from 5 to 12 μM in 48 hrs; OPM2, U266, NCI-H929, RPMI-8226), but not PBMCs (89% viability post 4-hr 100 μM SC75741 treatment). NF-κB inhibition by SC75741 treatment is reported to effectively block influenza virus propagation both in cultures in vitro (1-5 μM) and in mice in vivo (5 mg/kg daily i.v. or 7.5-15 mg/kg twice a day i.p.). |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥97% (HPLC) |
| Storage Temp. |
2-8°C |
| UNSPSC |
12352200 |
